VRAX
Virax Biolabs Group Limited
There isn't enough reported data to score VRAX yet.
VRAX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate VRAX's fundamentals.
VRAX PE Valuation
VRAX has no meaningful PE right now: it lost money over the past year.
VRAX Forward outlook
There aren't enough analyst estimates for VRAX to show an outlook.
VRAX Earnings Per Share
VRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $12.4K | +802% |
| Q3 2025 | $1.6K | -68% |
| Q1 2025 | $1.4K | -98% |
| Q3 2024 | $5K | -94% |
| Q1 2024 | $79.9K | +2753% |
| Q3 2023 | $76.5K | +1228% |
| Q1 2021 | $109.8K | +340% |
| Q3 2020 | $14K | -81% |
VRAX's revenue has slid since its 2021 peak: $12,423 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -51515% | -46773 points |
| Q3 2025 | -160788% | -157251 points |
| Q1 2025 | -238317% | -85079 points |
| Q3 2024 | -58124% | -33114 points |
| Q1 2024 | -4743% | N/A |
| Q3 2023 | -3538% | N/A |
| Q1 2023 | -153238% | -152989 points |
| Q3 2022 | -25010% | -22357 points |
VRAX's operating margin was −51515% last quarter, down 46773 points from the same quarter a year ago.
VRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.9M | -$1.9M |
| Q3 2025 | -$3.1M | -$898.3K |
| Q1 2025 | -$3M | +$248.4K |
| Q3 2024 | -$2.2M | +$2M |
| Q1 2024 | -$3.2M | -$1.2M |
| Q3 2023 | -$4.2M | -$1.9M |
| Q1 2023 | -$2.1M | -$1.5M |
| Q3 2022 | -$2.3M | -$2M |
VRAX has burned cash in almost every quarter: −$13M over the past year, against −$12M the year before.
VRAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.3% | +16.2K shares |
| 1 year | +168% | +120K shares |
VRAX has 190,520 diluted shares, up 168% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q1 2024 | $85,500 |
| Q3 2023 | — |
| Q1 2023 | — |
| Q3 2022 | — |
VRAX Net Leverage
VRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.5 | Oversold |
| Stochastic | 3.7 | Oversold |
VRAX's weekly RSI is 29 (oversold) and its Stochastic is 4 (oversold).
VRAX PE vs Healthcare Sector
VRAX has no meaningful PE right now: it lost money over the past year.
VRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.48 | 55% below |
| 20 week MA | $2.42 | 72% below |
| 50 week MA | $4.59 | 85% below |
| 100 week MA | $15.9 | 96% below |
| 200 week MA | $44.9 | 99% below |
VRAX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
VRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $2,585.0 | $142.5 | -94% |
| 2023 | $142.5 | $36.5 | -74% |
| 2024 | $36.5 | $52.5 | +44% |
| 2025 | $52.5 | $8.98 | -83% |
| 2026 YTD | $8.98 | $0.67 | -93% |
VRAX has finished lower in three of the last four years. It's down 93% so far in 2026.